Riboway Therapeutics: Redefining the undruggable
Riboway Therapeutics, 2025 BIO Start-Up Stadium winner, decodes hidden RNA events to enable drugging targets once thought impossible.| Bio.News
Riboway Therapeutics, 2025 BIO Start-Up Stadium winner, decodes hidden RNA events to enable drugging targets once thought impossible.| Bio.News
Bio.News spoke with the National Psoriasis Foundation to discuss federal and local action toward patient-centered psoriatic disease care.| Bio.News
Biotech firms weighing an IPO must consider timing, interest in their product, and macro environment said a BIO Investor Forum panel.| Bio.News
A Rat sarcoma (RAS) mutation is an oncogene, a gene that causes cancer when mutated. The RAS is the most commonly mutated oncogene in […] The post Startup Stadium: Tezcat Biosciences targets common cancer mutation appeared first on Bio.News.| Bio.News
Over 8 million people in the U.S., and 125 million worldwide, live with psoriasis—about 2–3% of the population. Far from being a simple cosmetic […] The post Psoriasis awareness: The condition is more than skin deep appeared first on Bio.News.| Bio.News
M&A in biotech has slowed from its peak in 2023 but there are still deals to be done, especially for companies who can present […] The post BIO 2025: As M&A slows, biotechs need to show good data appeared first on Bio.News.| Bio.News
“Initial weight loss is just the first chapter,” said Mia de Graaf, Deputy Executive Health Editor at Business Insider, “but the real challenge and […] The post BIO 2025: How weight loss drugs are disrupting chronic disease appeared first on Bio.News.| Bio.News
When experts discussed clinical uses of psychedelics two years ago at the 2023 Biotechnology Innovation Organization (BIO) International Convention, there was some interest in […] The post BIO 2025: Psychedelics go mainstream – what’s next? appeared first on Bio.News.| Bio.News
For most of her life, the only things coming out of left field for Kristin Smedley were fly balls, but with the birth of […] The post Mother inspired to support solutions for her boys’ blindness appeared first on Bio.News.| Bio.News
As drug makers work to develop safe, effective gene therapies, their progress can be slowed when they challenge the limits of established regulatory guidance […] The post BIO experts discuss challenges and offer opportunities for developing redosable gene therapies appeared first on Bio.News.| Bio.News
The federal government’s program that provides seed funding to support research by biotech startups provides much more than money, said program officials and small […] The post BIO 2025: Federal seed funding also comes with valuable advice appeared first on Bio.News.| Bio.News
Litigation opposing drug price controls in the Inflation Reduction Act (IRA) has yet to have a major impact, but the cases are still ongoing […] The post BIO 2025: Legal experts break down cases against IRA price controls appeared first on Bio.News.| Bio.News
BIO's 2025 report on the state of emerging biotechs finds that the landscape is challenging, though opportunities exist.| Bio.News
Bio.News is a daily news website exploring the wonders of biotechnology and the intersection of biotech innovation and U.S. and international policy.| Bio.News
What are biomarkers, and why do they matter? Dr. Colleen Pietras, M.D., explains why biomarkers matter to patients and drug development.| Bio.News
Keep up with the latest global discoveries, top experts and panelists at BIO International Convention.| Bio.News
Learn about BIO's views and positions on topics such as bioeconomy, biofuels and healthcare.| Bio.News
New political uncertainty could pose challenges for a slowly improving biotech M&A market, said panelists at BIO CEO 2025.| Bio.News
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do […]| Bio.News
PBMs make billions while driving up the price of drugs with markups that can exceed 1,000%, according to an FTC report released Jan. 14.| Bio.News
The accelerated approval pathway provides incredible benefit to patients with serious unmet medical need, and there’s data to back it up.| Bio.News
The Centers for Medicare & Medicaid Services (CMS) issued a directive telling private insurers providing Medicare Advantage (MA) plans to cover Biogen’s amyotrophic lateral sclerosis […]| Bio.News
The U.S. bioscience industry generated $3.2 trillion in output in 2023, according to a report from BIO and CSBA in partnership with TEConomy.| Bio.News
FTC released an interim report criticizing the negative impact pharmacy benefit manager (PBMs) have on prescription drug prices and access.| Bio.News
PBM industry that has driven reimbursement so low as to threaten the viability of local community pharmacies.| Bio.News
Rather than incentivizing PBMs to seek out medicines with high prices, there is a movement to “delink” price and PBM compensation.| Bio.News
BIO shares its strategic priorities to improve policy that impacts biotechnology and to foster an ecosystem where innovation can thrive.| Bio.News
PBMs save money with “step therapy,” which tries to displace a provider’s clinical judgment in favor of the medicine selected by the PBM.| Bio.News
